業績

2014年 研究業績

英文総説
  1. 1.Teshima T.: JAK inhibitors: a home run for GVHD patients?. Blood. 123(24). 3691-3693. 2014
英文原著
  1. 1.Nakasone H, Fukuda T, Kanda J, Mori T, Yano S, Kobayashi T, Miyamura K, Eto T, Kanamori H, Iwato K, Uchida N, Mori S, Nagamura-Inoue T, Ichinohe T, Atsuta Y, Teshima T, Murata M.: Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation.Bone Marrow Transplant. 2014 Dec 22. [Epub ahead of print]
  2. 2.Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, Urbano-Ispizua A, Cutler CS, Bacigalupo AA, Battiwalla M, Flowers ME, Juckett MB, Lee SJ, Loren AW, Klumpp TR, Prockup SE, Ringdén OT, Savani BN, Socié G, Schultz KR, Spitzer T, Teshima T, Bredeson CN, Jacobsohn DA, Hayashi RJ, Drobyski WR, Frangoul HA, Akpek G, Ho VT, Lewis VA, Gale RP, Koreth J, Chao NJ, Aljurf MD, Cooper BW, Laughlin MJ, Hsu JW, Hematti P, Verdonck LF, Solh MM, Norkin M, Reddy V, Martino R, Gadalla S, Goldberg JD, McCarthy PL, Pérez-Simón JA, Khera N, Lewis ID, Atsuta Y, Olsson RF, Saber W, Waller EK, Blaise D, Pidala JA, Martin PJ, Satwani P, Bornhäuser M, Inamoto Y, Weisdorf DJ, Horowitz MM, Pavletic SZ; Graft-vs-Host Disease Working Committee of the CIBMTR.: Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation - A Report from CIBMTR. Biol Blood Marrow Transplant. 2014 Oct 30. [Epub ahead of print]
  3. 3.Shiratori S, Fujimoto K, Nishimura M, Hatanaka KC, Kosugi-Kanaya M, Okada K, Sugita J, Shigematsu A, Hashimoto D, Endo T, Kondo T, Abe R, Hashino S, Matsuno Y, Shimizu H, Teshima T.: Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome. Hematol Oncol. 2014 Oct 14. [Epub ahead of print]
  4. 4.Kasamatsu J, Takahashi S, Azuma M, Matsumoto M, Morii-Sakai A, Imamura M, Teshima T, Takahashi A, Hirohashi Y, Torigoe T, Sato N, Seya T.: PolyI:C and mouse survivin artificially embedding human 2B peptide induce a CD4+ T cell response to autologous survivin in HLA-A*2402 transgenic mice. Immunobiology. 2014 Aug 23. [Epub ahead of print]
  5. 5.Tsutsumi Y, Shimono J, Ohhigashi H, Ito S, Shiratori S, Teshima T.: Analysis of the influence of dabigatran on coagulation factors and inhibitors.Int J Lab Hematol.2014 Jun 25. [Epub ahead of print]
  6. 6.Takahata M, Hashino S, Onozawa M, Shigematsu A, Sugita J, Fujimoto K, Endo T, Kondo T, Tanaka J, Imamura M, Teshima T.: Hepatitis B virus (HBV) reverse seroconversion (RS) can be prevented even in non-responders to hepatitis B vaccine after allogeneic stem cell transplantation: long-term analysis of intervention in RS with vaccine for patients with previous HBV infection. Transpl Infect Dis. 16(5). 797-801. 2014
  7. 7.Iwasaki J, Kondo T, Darmanin S, Ibata M, Onozawa M, Hashimoto D, Sakamoto N, Teshima T.: FIP1L1 presence in FIP1L1-RARA or FIP1L1-PDGFRA differentially contributes to the pathogenesis of distinct types of leukemia. Ann Hematol. 93(9). 1473-1481. 2014
  8. 8.Leemhuis T, Padley D, Keever-Taylor C, Niederwieser D, Teshima T, Lanza F, Chabannon C, Szabolcs P, Bazarbachi A, Koh MB.: Essential requirements for setting up a stem cell processing laboratory. Bone Marrow Transplant. 49(8). 1098-1105. 2014
  9. 9.Takashima S, Miyamoto T, Kadowaki M, Ito Y, Aoki T, Takase K, Shima T, Yoshimoto G, Kato K, Muta T, Shiratsuchi M, Takenaka K, Iwasaki H, Teshima T, Kamimura T, Akashi K.: Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients. Int J Hematol. 100(2). 159-164. 2014
  10. 10.Shigematsu A, Kobayashi N, Yasui H, Shindo M, Kakinoki Y, Koda K, Iyama S, Kuroda H, Tsutsumi Y, Imamura M, Teshima T.: High level of serum soluble interleukin-2 receptor at transplantation predicts poor outcome of allogeneic stem cell transplantation for adult T cell leukemia. Biol Blood Marrow Transplant. 20(6). 801-805. 2014
  11. 11.Shiratori S, Wakasa K, Okada K, Sugita J, Akizawa K, Shigematsu A, Hashimoto D, Fujimoto K, Endo T, Kondo T, Shimizu C, Hashino S, Teshima T.: Stenotrophomonas maltophilia infection during allogeneic hematopoietic stem cell transplantation: a single-center experience. Clin Transplant. 28(6). 656-661. 2014
  12. 12.Shono Y, Shiratori S, Kosugi-Kanaya M, Ueha S, Sugita J, Shigematsu A, Kondo T, Hashimoto D, Fujimoto K, Endo T, Nishio M, Hashino S, Matsuno Y, Matsushima K, Tanaka J, Imamura M, Teshima T.: Bone marrow graft-versus-host disease: evaluation of its clinical impact on disrupted hematopoiesis after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 20(4). 495-500. 2014
  13. 13.Takashima S, Miyamoto T, Kamimura T, Yoshimoto G, Kato K, Ito Y, Muta T, Matsushima T, Shiratsuchi M, Tanimoto K, Takenaka K, Iwasaki H, Teshima T and Akashi K.: Comparison of bortezomib, cyclophosphamide, and dexamethasone (VCD) induction with bortezomib and dexamethasone (BD) induction for newly diagnosed symptomatic multiple myeloma. International Journal of Myeloma. 4(1). 7-12. 2014
  14. 14.Sugiyama H, Maeda Y, Nishimori H, Yamasuji Y, Matsuoka KI, Fujii N, Kondo E, Shinagawa K, Tanaka T, Takeuchi K, Teshima T, Tanimoto M.: Mammalian target of rapamycin inhibitors permit regulatory T cell reconstitution and inhibit experimental chronic graft-versus-host disease. Biol Blood Marrow Transplant. 20(2). 183-191. 2014
  15. 15.Koyama M, Hashimoto D, Nagafuji K, Eto T, Ohno Y, Aoyama K, Iwasaki H, Miyamoto T, Hill GR, Akashi K, Teshima T.: Expansion of donor-reactive host T cells in primary graft failure after allogeneic hematopoietic SCT following reduced-intensity conditioning. Bone Marrow Transplant. 49(1). 110-115. 2014
  16. 16.Takashima S, Eto T, Shiratsuchi M, Hidaka M, Mori Y, Kato K, Kamezaki K, Oku S, Henzan H, Takase K, Matsushima T, Takenaka K, Iwasaki H, Miyamoto T, Akashi K, Teshima T.: The use of oral beclomethasone dipropionate in the treatment of gastrointestinal graft-versus-host disease: the experience of the Fukuoka blood and marrow transplantation (BMT) group. Intern Med. 53(12). 1315-1320. 2014
  17. 17.Kobayashi R, Tanaka J, Hashino S, Ota S, Dr. Torimoto Y, Kakinoki Y, Dr. Yamamoto S, Kurosawa M, Hatakeyama N, Haseyama Y, Sakai H, Sato K, Fukuhara T.: Etoposide-containing conditioning regimen reduces the occurrence of hemophagocytic lymphohistiocytosis after stem cell transplantation. Bone Marrow Transplant. 49(2). 254-257. 2014
  18. 18.Morita R, Nishizawa S, Torigoe T, Takahashi A, Tamura Y, Tsukahara T, Kanaseki T, Sokolovskaya A, Kochin V, Kondo T, Hashino S, Asaka M, Hara I, Hirohashi Y, Sato N.: Heat shock protein DNAJB8 is a novel target for immunotherapy of colon cancer-initiating cells. Cancer Sci. 105(4). 389-395. 2014
  19. 19.Sano H, Kobayashi R, Tanaka J, Hashino S, Ota S, Torimoto Y, Kakinoki Y, Yamamoto S, Kurosawa M, Hatakeyama N, Haseyama Y, Sakai H, Sato N, Fukuhara T.: Risk factor analysis of non-Hodgkin lymphoma-associated haematophagocytic syndrome: a multicenter study. Br J Haematol. 165(6). 786-792. 2014
  20. 20.Hanamatsu H, Ohnishi S, Sakai S, Yuyama K, Mitsutake S, Takeda H, Hashino S, Igarashi Y.: Altered levels of serum sphingomyelin and ceramide containing distinct acyl chains in young obese adults. Nutr Diabetes. Oct 20;4:e141. 2014
  21. 21.Hirayama Y, Ishitani K, Ota S, Kurosawa M, Kondo T, Takimoto R, Mori A, Sakai H, Torimoto Y, Yamamoto S, Sato K, Iwasaki H, Kohda K, Ishida T, Kakinoki Y, Fukuhara T, Kato J.: Long-term survey of survival time, histological transformation, and secondary malignancies in Japanese patients with advanced-stage follicular lymphoma in the rituximab era: Hokkaido Hematology Study Group. Int J Hematol. 100(3). 281-289. 2014
  22. 22.Takahashi N, Miura M, Kuroki J, Mitani K, Kitabayashi A, Sasaki O, Kimura H, Imai K, Tsukamoto N, Noji H, Kondo T, Motegi M, Kato Y, Mita M, Saito H, Yoshida C, Torimoto Y, Kimura T, Wano Y, Nomura J, Yamamoto S, Mayama K, Honma R, Sugawara T, Sato S, Shinagawa A, Abumiya M, Niioka T, Harigae H, Sawada K.: Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib. Biomark Res. 2(1). 6. 2014
  23. 23.Li P, Fujimoto K, Bourguingnon L, Yukl S, Deeks S, Wong JK.: Exogenous and endogenous hyaluronic acid reduces HIV infection of CD4+ T cells. Immunol Cell Biol. 92(9). 770-780. 2014
  24. 24.Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M, Ueda R.: Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 32(11). 1157-1163. 2014
  25. 25.Muller PA, Kosco B, Rajani GM, Stevanovic K, Berres ML, Hashimoto D, Mortha A, Leboeuf M, Li XM, Mucida D, Stanley ER, Dahan S, Margolis KG, Gershon MD, Merad M, Bogunovic M. : Crosstalk between muscularis macrophages and enteric neurons regulates gastrointestinal motility. Cell. 158(2). 300-313. 2014
  26. 26.Mortha A, Chudnovskiy A, Hashimoto D, Bogunovic M, Spencer SP, Belkaid Y, Merad M. : Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis. Science. 343(6178). 1249288-1-1249288-7. 2014
  27. 27.Jiao J, Dragomir AC, Kocabayoglu P, Rahman AH, Chow A, Hashimoto D, Leboeuf M, Kraus T, Moran T, Carrasco-Avino G, Friedman SL, Merad M, Aloman C. : Central role of conventional dendritic cells in regulation of bone marrow release and survival of neutrophils. J Immunol. 192(7). 3374-3382. 2014
  28. 28.Bongers G, Pacer ME, Geraldino TH, Chen L, He Z, Hashimoto D, Furtado GC, Ochando J, Kelley KA, Clemente JC, Merad M, van Bakel H, Lira SA. : Interplay of host microbiota, genetic perturbations, and inflammation promotes local development of intestinal neoplasms in mice. J Exp Med. 211(3). 457-472. 2014
  29. 29.Agudo J, Ruzo A, Tung N, Salmon H, Leboeuf M, Hashimoto D, Becker C, Garrett-Sinha LA, Baccarini A, Merad M, Brown BD. : The miR-126-VEGFR2 axis controls the innate response to pathogen-associated nucleic acids. Nat Immunol. 15(1). 54-62. 2014
  30. 30.Gough SM, Lee F, Yang F, Walker RL, Zhu YJ, Pineda M, Onozawa M, Chung YJ, Bilke S, Wagner EK, Denu JM, Ning Y, Xu B, Wang GG, Meltzer PS, Aplan PD.: NUP98-PHF23 is a chromatin-modifying oncoprotein that causes a wide array of leukemias sensitive to inhibition of PHD histone reader function. Cancer Discov. 4(5). 564-577. 2014
  31. 31.Onozawa M, Zhang Z, Kim YJ, Goldberg L, Varga T, Bergsagel PL, Kuehl WM, Aplan PD. : Repair of DNA double-strand breaks by templated nucleotide sequence insertions derived from distant regions of the genome. Proc Natl Acad Sci U S A. 111(21). 7729-7734. 2014
  32. 32.Santos MA, Faryabi RB, Ergen AV, Day AM, Malhowski A, Canela A, Onozawa M, Lee JE, Callen E, Gutierrez-Martinez P, Chen HT, Wong N, Finkel N, Deshpande A, Sharrow S, Rossi DJ, Ito K, Ge K, Aplan PD, Armstrong SA, Nussenzweig A. : DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier. Nature. 514(7520). 107-111. 2014
  33. 33.Shigematsu A, Kobayashi N, Yasui H, Shindo M, Kakinoki Y, Koda K, Iyama S,Kuroda H, Tsutsumi Y, Imamura M, Teshima T.: High level of serum soluble interleukin-2 receptor at transplantation predicts poor outcome of allogeneic stem cell transplantation for adult T cell leukemia. Biol Blood Marrow Transplant. 20(6). 801-805. 2014
  34. 34.Nakano K, Moriyama T, Yasuda K, Shibuya H, Tajima T, Shigematsu A, Shimizu C. : Identification of IgG-κ type macroprolactin found in the serum of an 8-year-old girl. Clin Chim Acta. 10(433). 206-208. 2014
  35. 35.Nabekura T, Kanaya M, Shibuya A, Fu G, Gascoigne NR, Lanier LL.: Costimulatory molecule DNAM-1 is essential for optimal differentiation of memory natural killer cells during mouse cytomegalovirus infection. Immunity. 40(2). 225-234. 2014
英文症例報告
  1. 1.Tsutsumi Y, Shimono J, Miyashita N, Teshima T.: “No effect of humanized CCR monoclonal antibody (Mogamulizumab) on treatment-resistant adult T-cell leukemia with meningeal infiltration.”. Leuk Lymphoma (letter). 55(2). 457-459. 2014
  2. 2.Hayase E, Fujimoto K, Mitsuhashi T, Hatanaka Y, Yoshida M, Takemura R, Iwasaki J, Shiratori S, Sugita J, Kondo T, Tanaka J, Imamura M, Matsuno Y, Teshima T.: Epstein-barr virus-associated smooth muscle tumors after bone marrow transplantation. Transplantation. 97(1). e1-e3. 2014
  3. 3.Ohe M, Hashino S.: Successful treatment of primary immune thrombocytopenia in aged patients using clarithromycin. J Formos Med Assoic. 113(3). 197-198. 2014
  4. 4.Tsunematsu S, Natsuizaka M, Fujita H, Otsuka N, Terashita K, Sato F, Kobayashi T, Nakai M, Tsukuda Y, Horimoto H, Sho T, Suda G, Nakanishi M, Hashino S, Chuma M, Sakamoto N.: Hepatosplenic gamma-delta T-cell lymphoma associated with Epatein-Barr virus. Intern Med. 53(18). 2078-2082. 2014
和文総説
  1. 1.豊嶋 崇徳. : 移植後GVHDの分子病態と治療. 血液内科. 68(3). 291-297. 2014
  2. 2.杉田 純一,豊嶋 崇徳. : Graft-versus-host disease制御. 臨床血液. 55(2). 170-176. 2014
  3. 3.杉田 純一, 豊嶋 崇徳. : HLA半合致移植. 血液フロンティア. 24(7). 1344-6940. 2014
  4. 4.高畑 むつみ,豊嶋 崇徳. : 臍帯血移植における移植片対宿主病(GVHD). 医学のあゆみ. 249(7). 587-592. 2014
  5. 5.早瀬 英子,橋本 大吾,豊嶋 崇徳. : 造血幹細胞移植後GVHDと消化管傷害. 最新医学. 69(3). 503-507. 2014
  6. 6.橋本 大吾. : マク口ファージは末梢組織でも自己増殖する?!. 炎症と免疫. 22(6). 411-415. 2014
和文著書
  1. 1.豊嶋 崇徳.: GVHD (移植片対宿主病)と造血細胞移植 豊嶋崇徳編集,医薬ジャーナル社. 全136頁. 2014
  2. 2.近藤 健, 豊嶋 崇徳. : 第1寛解期AMLにおける造血幹細胞移植の適応. EBM 血液疾患の治療 2015-2016 金倉譲, 木崎昌弘,鈴木律朗,神田善伸編集,中外医学社. 79-84. 2014
  3. 3.杉田 純一.: 移植後シクロホスファミドを用いたHLA不適合血縁者間移植の位置づけ. EBM 血液疾患の治療 2015-2016 金倉譲, 木崎昌弘,鈴木律朗,神田善伸編集,中外医学社. 510-515. 2014
  4. 4.小野澤 真弘.: 造血幹細胞移植後のB型肝炎ウイルスワクチンの有用性は?.EBM 血液疾患の治療 2015-2016 金倉譲, 木崎昌弘,鈴木律朗,神田善伸編集,中外医学社. 546-548. 2014
  5. 5.豊嶋 崇徳.: GVHD 第3版. 造血細胞移植学会ガイドライン 第1巻 日本造血細胞移植学会ガイドライン委員会編集,医薬ジャーナル社. 60-125. 2014
  6. 6.豊嶋 崇徳.: 急性GVHDの分子病態とバイオマーカー. Annual Review 血液 2014 高久史麿, 小澤敬也, 坂田洋一, 金倉譲, 小島勢二編集,中外医学社. 38-43. 2014
  7. 7.重松 明男,豊嶋 崇徳.: 造血幹細胞移植の前処置. 血液疾患 最新の治療2014-2016 直江知樹, 小澤敬也, 中尾眞二編集,南江堂. 271-275.2014
  8. 8.安藤 雄一, 豊嶋 崇徳.: MKSAP16 血液学・腫瘍学(日本語版No.1~6) 豊嶋崇徳,安藤雄一監修,株式会社ヘスコインターナショナル. 全120頁. 2014
  9. 9.近藤 健.: 血小板減少症. 消化器がん化学療法副作用マネジメント プロのコツ 小松嘉人編集, メジカルビュー社. 294-297. 2014
  10. 10.近藤 健.: 貧血. 消化器がん化学療法副作用マネジメント プロのコツ 小松嘉人編集, メジカルビュー社. 298-301.2014
  11. 11.遠藤 知之.: ヘモクロマトーシス. 今日の治療指針 2014年版 山口徹,北原光夫監修/福井次矢,高木誠,小室一成総編集,医学書院. 702-703. 2014
  12. 12.遠藤 知之.: 抗HIV療法: 治療の失敗とサルベージ療法. HIV感染症とAIDS 第2版 満屋裕明編集,最新医学社. 138-146. 2014
和文原書
  1. 1.藤本 勝也, 遠藤 知之, 吉田 美穂, 竹村 龍, 近藤 健, 橋野 聡, 須田 剛生, 中馬 誠, 後藤 了一, センテノ田村 恵子, 渡部 恵子, 大野 稔子, 石田 禎夫, 大竹 孝明, 宮城島 拓人, 小林 一, 堤 豊, 三宅 高義, 北川 浩彦, 佐藤 典宏, 豊嶋 崇徳.: 北海道内のHIV感染症患者におけるHBV・HCV重複感染の現状 -拠点病院・診療施設アンケート調査結果-. 日本エイズ学会誌. 16(1).18-27. 2014
  2. 2.吉村 彩、武藏 学、金子 壮朗、大西 俊介、折戸 智恵子、川原 由佳子、橋野 聡、森松 正美、今野 哲、有川 二郎、石井 哲也、澤村 正也、上田 一郎.: 北海道大学における動物実験実施者の実験動物への感作状況. アレルギー. 63(8). 1132-1139. 2014
和文症例報告
  1. 1.早瀬英子, 杉田純一, 藤本勝也, 江端浩, 山川知宏, 吉田美穂, 竹村龍, 岩﨑純子, 高橋正二郎, 白鳥聡一, 近藤健, 田中淳司, 豊嶋崇徳.: ビンクリスチンによる麻痺性イレウスに引き続きposterior reversible encephalopathy syndromeを発症したT細胞性リンパ芽球性リンパ腫.臨床血液. 55(2). 249-253. 2014
  2. 2.山田 武宏, 白鳥 聡一, 杉田 純一, 藤本 勝也, 豊嶋 崇徳, 福元 達也, 岩崎 澄央, 秋沢 宏次, 鳴海 克哉, 石黒 信久, 井関 健.: チゲサイクリンとコリスチンの併用が奏功した多剤耐性アシネトバクター・バウマニによるカテーテル関連血流感染症の1例. 日本化学療法学会雑誌. 62(4). 501-505. 2014
和文その他
  1. 1.豊嶋 崇徳.: 【Meeting Report】第55回米国血液学会議(ASH2013). がん分子標的治療. 12(2). 121-123. 2014